Nomograms predicting prognosis of patients with pathological stages T1N2-3 and T3N0 gastric cancer

Table 1 Baseline characteristics of patients with pT1N2-3 and pT3N0 GC, n (%)

Characteristic	pT1N2-3b (n = 89)	pT3N0 (n = 370)	P value
Sex			< 0.001
Male	44 (49.4)	269 (72.7)
Female	45 (50.6)	101 (27.3)
Age (yr)			0.071
≤ 60	58 (65.2)	219 (59.2)
> 60	25 (34.8)	151 (40.8)
BMI (kg/m2)			0.964
< 24	63 (70.8)	261 (70.5)
≥ 24	26 (29.2)	109 (29.5)
Borrmann type			< 0.001
0	89 (100.0)	0 (0.0)
1	0 (0.0)	23 (6.2)
2	0 (0.0)	126 (34.1)
3	0 (0.0)	195 (52.7)
4 or 5	0 (0.0)	26 (7.0)
Tumor diameter (mm)			0.002
≤ 50	74 (83.1)	245 (66.2)
> 50	15 (16.9)	125 (33.8)
Tumor location			0.007
Upper	4 (4.5)	53 (14.3)
Middle	11 (12.4)	66 (17.8)
Lower	74 (83.1)	243 (65.7)
Total	0 (0.0)	8 (2.2)
Gastrectomy			0.001
Partial gastrectomy	83 (93.3)	289 (78.1)
Total gastrectomy	6 (6.7)	81 (21.9)
Histological type			0.043
Differentiated	32 (36.0)	177 (47.8)
Undifferentiated	57 (64.0)	193 (52.2)
pT stage			< 0.001
T1a	18 (20.2)	0 (0.0)
T1b	71 (79.8)	0 (0.0)
T3	0 (0.0)	370 (100.0)
pN stage			< 0.001
N0	0 (0.0)	370 (100.0)
N2	70 (78.7)	0 (0.0)
N3a	18 (20.2)	0 (0.0)
N3b	1 (1.1)	0 (0.0)
Vascular infiltration			0.021
No	64 (71.9)	306 (82.7)
Yes	25 (28.1)	64 (17.3)
Nerve infiltration			< 0.001
No	82 (92.1)	224 (60.5)
Yes	7 (7.9)	146 (39.5)
Postoperative chemotherapy			< 0.001
Yes	52 (58.4)	114 (30.8)
No	37 (41.6)	256 (69.2)

Tumor location, histological type, pT stage, pN stage, pTNM stage, vascular infiltration, and nerve infiltration were according to the postoperative pathology report. Statistically significant P values are in bold (P < 0.05). BMI: Body mass index.

Table 2 Univariate and multivariate analyses of clinicopathological factors of patients with pT1N2-3b GC

Characteristic	pT1N2-3b
	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Sex		0.870	-	-
Male	1.000
Female	0.929 (0.387-2.233)
Age (yr)	1.044 (1.001-1.089)	0.044	1.022 (0.978-1.069)	0.335
BMI (kg/m2)	0.924 (0.815-1.047)	0.216	-	-
Neutrophils (109/L)	1.034 (0.795-1.345)	0.802	-	-
Lymphocytes (109/L)	0.616 (0.297-1.278)	0.193	-	-
Platelets (109/L)	0.999 (0.992-1.006)	0.692	-	-
Fibrinogen (g/L)	1.277 (0.723-2.256)	0.399	-	-
ALT (U/L)	1.000 (0.973-1.029)	0.972	-	-
AST (U/L)	1.016 (0.968-1.067)	0.521	-	-
Albumin (g/L)	0.926 (0.833-1.028)	0.150	-	-
Prealbumin (mg/L)	0.986 (0.977-0.995)	0.003	0.990 (0.981-1.000)	0.040
CEA (ng/mL)	1.254 (1.074-1.464)	0.004	1.199 (1.028-1.399)	0.021
CA19-9 (U/mL)	1.000 (0.972-1.028)	0.992	-	-
Tumor diameter (mm)	0.986 (0.961-1.013)	0.307	-	-
Gastrectomy		0.683	-	-
Partial gastrectomy	1.000
Total gastrectomy	1.356 (0.314-5.851)
Histological type		0.324	-	-
Differentiated	1.000
Undifferentiated	1.665 (0.605-4.581)
pN stage		0.251	-	-
N2	1.000
N3	1.752 (0.673-4.562)
mLNR	47.797 (5.421-421.417)	< 0.001	17.488 (1.215-251.748)	0.035
Vascular infiltration		0.187	-	-
No	1.000
Yes	1.865 (0.738-4.708)
Nerve infiltration		0.989	-	-
No	1.000
Yes	1.010 (0.234-4.359)
Postoperative chemotherapy		0.528	-	-
Yes	1.000
No	0.744 (0.297-1.865)

CEA and CA19-9 were according to the tumor marker examination. Tumor location, histological type, mLNR, pTstage, pNstage, vascular infiltration, and nerve infiltration were according to the postoperative pathology report. Statistically significant P values are in bold (P < 0.05). HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; ALT: Alanine transaminase; AST: A CEA: Carcino-embryonic antigen; CA19-9: Carbohydrate antigen 19-9; mLNR: Metastatic lymph node ratio.

Table 3 Univariate and multivariate analyses of clinicopathological factors of patients with pT3N0 GC

Characteristic	pT3N0
	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Sex		0.087	-	-
Male	1.000
Female	1.533 (0940-2.500)
Age (yr)	1.029 (1.005-1.054)	0.019	1.025 (1.001-1.049)	0.039
BMI (kg/m2)	0.890 (0.822-0.964)	0.004	0.881 (0.812-0.955)	0.002
Neutrophils (109/L)	0.947 (0.829-1.082)	0.421	-	-
Lymphocytes (109/L)	0.966 (0.719-1.298)	0.819	-	-
Platelets (109/L)	1.000 (0.997-1.003)	0.914	-	-
Fibrinogen (g/L)	1.048 (0.974-1.129)	0.210	-	-
ALT (U/L)	0.992 (0.969-1.015)	0.469	-	-
AST (U/L)	1.012 (0.986-1.037)	0.369	-	-
Albumin (g/L)	0.991 (0.949-1.034)	0.670	-	-
Prealbumin (mg/L)	1.657 (0.954-2.005)	0.087	-	-
CEA (ng/mL)	1.007 (0.985-1.030)	0.535	-	-
CA19-9 (U/mL)	1.002 (0.999-1.004)	0.214	-	-
Tumor diameter (mm)	1.011 (1.004-1.019)	0.003	1.000 (0.990-1.010)	0.981
Borrmann type		0.018		0.282
1	1.000		1.000
2	0.368 (0.159-0.853)	0.020	0.473 (0.195-1.150)	0.099
3	0.520 (0.242-1.119)	0.095	0.620 (0.279-1.377)	0.240
4 or 5	1.110 (0.428-2.879)	0.830	1.051 (0.379-2.911)	0.924
Gastrectomy		< 0.001		< 0.001
Partial gastrectomy	1.000		1.000
Total gastrectomy	3.378 (2.105-5.421)		3.222 (1.945-5.338)
Histological type		0.380	-	-
Differentiated	1.000
Undifferentiated	1.236 (0.771-1.980)
Vascular infiltration		0.237	-	-
No	1.000
Yes	1.142 (0.798-2.499)
Nerve infiltration		0.373	-	-
No	1.000
Yes	1.240 (0772-1.991)
Postoperative chemotherapy		0.238	-	-
Yes	1.000
No	0.774 (0.430-1.393)

CEA and CA19-9 were according to the tumor marker examination. Tumor location, histological type, mLNR, pTstage, pNstage, vascular infiltration, and nerve infiltration were according to the postoperative pathology report. Statistically significant P values are in bold (P < 0.05). HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; ALT: Alanine transaminase; AST: A CEA: Carcino-embryonic antigen; CA19-9: Carbohydrate antigen 19-9; mLNR: Metastatic lymph node ratio.